Mesoblast Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MESO research report →
About the company
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases.
- CEO
- Silviu Itescu
- IPO
- 2010
- Employees
- 73
- HQ
- Melbourne, VIC, AU
Price Chart
- Market Cap
- $1.86B
- P/E
- -19.43
- P/S
- 28.28
- P/B
- 3.21
- EV/EBITDA
- -28.83
- Div Yield
- 0.00%
- Gross Margin
- -53.34%
- Op Margin
- -223.08%
- Net Margin
- -144.33%
- ROE
- -16.10%
- ROIC
- -20.16%
- Revenue
- $17.20M · 191.39%
- Net Income
- $-102,142,000 · -16.13%
- EPS
- $-0.84 · 5.27%
- Op Income
- $-62,443,000
- FCF YoY
- -3.88%
- 52W High
- $21.50
- 52W Low
- $10.32
- 50D MA
- $14.74
- 200D MA
- $16.22
- Beta
- 0.80
- Avg Volume
- 190.65K
Get TickerSpark's AI analysis on MESO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | COBLEY LYNETTE ELIZABETH | other | 0 |
| Mar 18, 26 | COBLEY LYNETTE ELIZABETH | other | 0 |
| Mar 18, 26 | COBLEY LYNETTE ELIZABETH | other | 200,000 |
| Apr 9, 26 | George Gregory | buy | 10,000 |
| Apr 9, 26 | George Gregory | buy | 10,000 |
| Apr 9, 26 | George Gregory | buy | 10,000 |
| Apr 9, 26 | George Gregory | buy | 5,000 |
| Apr 9, 26 | George Gregory | buy | 10,000 |
| Apr 9, 26 | George Gregory | buy | 5,240 |
| Apr 9, 26 | George Gregory | buy | 10,000 |
Our MESO coverage
Recent articles, reports, and earnings notes.
No research on MESO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MESO report →Similar companies
Peers in the same neighborhood.